Now recruiting
We are enrolling patients in the clinical studies below. Participation is voluntary, free of charge and includes close follow-up by our cardiology team.
Final eligibility is always confirmed by the investigator after an evaluation visit. Reaching out does not commit you to participate.
003Pacibekitug vs. placebo
Adults who have had a heart attack (myocardial infarction) and remain at high cardiovascular risk.
A randomized, double-blind, placebo-controlled, multi-center trial assessing the effect of pacibekitug on major cardiovascular events in participants after a myocardial infarction and at high cardiovascular risk.
FIN-21049Finerenone in HFrEF
People with heart failure with reduced ejection fraction who cannot take, or did not tolerate, spironolactone or eplerenone.
FINALITY-HF — Finerenone in HFrEF patients intolerant of or ineligible for steroidal MRA.
004Polypill and colchicine
People with established atherosclerotic cardiovascular disease, such as prior heart attack, stroke or peripheral artery disease.
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (EPOCA).
NCT06008197Finerenone in HFmrEF/HFpEF
People with heart failure with mildly reduced or preserved ejection fraction, recently hospitalized for a decompensation.
REDEFINE-HF — Finerenone in HFmrEF/HFpEF after acute decompensation.